Immatics (IMTX) Non-cash Items (2020 - 2021)
Immatics recorded quarterly Non-cash Items of $27.4 million in Q2 2021, down 85.71% quarter-over-quarter from $191.8 million in Q3 2020.
Immatics' Non-cash Items history runs 2 years deep, the most recent figure standing at $27.4 million for Q2 2021.
- In Q2 2021, Non-cash Items changed N/A year-over-year to $27.4 million; the TTM figure through Jun 2021 stood at $27.4 million (changed N/A YoY), while the FY2020 annual figure was $172.4 million, changed N/A from the prior year.
- Non-cash Items came in at $27.4 million for Q2 2021 at Immatics, down from $191.8 million in the prior quarter.
- In the past five years, Non-cash Items ranged from a high of $191.8 million in Q3 2020 to a low of $27.4 million in Q2 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Immatics | 1.80 Bn | 1.80 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 27.41 Mn |
| Jun 30, 2021 | 27.41 Mn |
| Sep 30, 2020 | 191.83 Mn |
| Sep 30, 2020 | 191.83 Mn |